CANY
SNDX icon

Caxton Associates (New York)’s Syndax Pharmaceuticals SNDX Stock Holding History

Caxton Associates (New York)’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,576
Closed -$615K – 596
2022
Q3 		$615K Buy
+25,576
New +$574K 0.08% 198
2020
Q2 		– Sell
-20,326
Closed -$223K – 609
2020
Q1 		$223K Buy
+20,326
New +$191K 0.04% 327

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Caxton Associates (New York)'s SNDX Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Syndax Pharmaceuticals (SNDX) in Q4 2022, closing a stake of 25,576 shares — an estimated $615K sold.

Caxton Associates (New York) first reported a position in SNDX in Q1 2020 and held it in 2 quarters. The position peaked at $615K in Q3 2022. 159 funds tracked by Wall St. Rank hold SNDX as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Syndax Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 25,576 Syndax Pharmaceuticals shares in Q4 2022, an estimated $615K.
  • Caxton Associates (New York) first reported a position in Syndax Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Syndax Pharmaceuticals position peaked at $615K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.